The Left Front has started mobilising the support of non-NDA and non-UPA parties to garner support against the Congress-led UPA government's move to push its economic reforms agenda with three much-delayed financial sector legislations. The Left Front will reach out to regional parties, including AIADMK, Samajwadi Party, Janata Dal (Secular), Biju Janata Dal and Asom Gana Parishad, to gather numbers against the legislations. Despite reservations expressed by UPA ally Trinamool Congress,...

Imagine you are a citizen racing across newspapers rapid fire. As you flip the pages you run across events like the Vedanta mining case, the Koodankulam nuclear controversy, the debate on poverty and reports about climate change. Each of these can be a life-threatening event and none of them have a life support system of knowledge which allows them to be debated in the open. The basic information comes from...

The country is clearly shaping its legislation to promote access to medicines by fostering generic production. INDIA'S approach to the revision of its Patents Act in 2005 is a clear example of a country shaping its legislation to promote access to medicines by fostering generic production. Although World Trade Organisation (WTO) rules made it mandatory for India to put in place a patent regime for medicines by 2005, nothing obliges...

The implementation of Patents Act, as last amended in 2005, raises significant issues of immediate concern to patients across the world. INDIA'S Patents Act has an interesting history. Enacted first in 1911 as the Indian Patents and Designs Act in the colonial era, it primarily addressed the interests of inventors, who did not want their inventions infringed upon by anyone who copied them or adopted the methods used to make them....

Industry reacts with caution to the grant of a compulsory licence to Natco, but cancer patients welcome it and hope for many more. THE first compulsory licence (CL) issued by the Indian patent office, to the local drug manufacturer Natco Pharma Ltd to sell the generic version of Bayer AG's anti-cancer drug Nexavar, has led to varied reactions. The landmark decision has also raised concerns about the outcome of cases...